BCG vaccine immunity against human tuberculosis. The BCG vaccine can be anywhere from 0 to 80% effective in preventing tuberculosis for a duration of 15 years; however, its protective effect appears to vary according to geography and the lab in which the vaccine strain was grown. A number of different companies make BCG, sometimes using different genetic strains of the bacterium. This may result in different product characteristics. OncoTICE, used for bladder instillation for bladder cancer, was developed by Organon Laboratories (since acquired by Schering-Plough, and in turn acquired by Merck & Co.). Pacis BCG, made from the Montréal (Institut Armand-Frappier) strain,
Inoculation needle to the needle so that the needle tip is submerged while maintaining the needle's original position. Careful swirling of the needle can help the inoculation of the microorganism from the needle to the sterile broth. The inoculated broth culture is then removed from the needle. Aseptic technique is applied to the open end of the broth culture to prevent contaminants, and the needle is flamed for sterilization. An inoculation needle is used to inoculate a slant culture in a fish tail inoculation technique. After the microorganisms transfer from the original microbial culture to the inoculation needle the sterile slant culture